We used Western blotting to verify HER-2 overexpression in ER-overexpressing and triple-negative breast cancer cell lines (data not shown); moreover, we used the MTT test to compare cell transfection in HER-2-overexpressing and HER-2-non-overexpressing cell lines. Here, ERBB2 is linked to triple-negative breast carcinoma.